Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.
Preclinical Research The efficacy of anti-TNF agents in the treatment of multiple immune-mediated inflammatory diseases (IMIDs) has increased their daily use. However, concerns remain regarding their long-term safety profile. Using a literature-based review of the infectious and malignant complications of anti-TNF biologics in IMIDs including psoriasis, Rheumatoid Arthritis, and inflammatory bowel disease, this review presents current evidence relative to the safety of anti-TNF agents in the context infections and malignancy in adults with IMIDs. Treatment with anti-TNF biologics is an effective treatment option with known risks that can be mitigated by appreciating the safety aspects and via a thorough screening and continuous monitoring of the patient.
Instituto de Ciências Biomédicas Abel Salazar, Centro Hospitalar do Porto, Portugal.
Rui
R
Pereira
Instituto de Ciências Biomédicas Abel Salazar, Centro Hospitalar do Porto, Portugal.|Department of Gastroenterology, Centro Hospitalar do Porto, Portugal.
Paula
P
Lago
Instituto de Ciências Biomédicas Abel Salazar, Centro Hospitalar do Porto, Portugal.|Clinical Immunology Unit, Centro Hospitalar do Porto, Portugal.
Raquel
R
Faria
Instituto de Ciências Biomédicas Abel Salazar, Centro Hospitalar do Porto, Portugal.|Department of Dermatology, Centro Hospitalar do Porto, Portugal.
Tiago
T
Torres
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy*; D007239:Infections / Q000139:chemically induced / Q000209:etiology* / Q000276:immunology; D007249:Inflammation / Q000188:drug therapy*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D009369:Neoplasms / Q000139:chemically induced / Q000209:etiology* / Q000276:immunology; D009894:Opportunistic Infections / Q000139:chemically induced / Q000209:etiology / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha
anti-TNFa therapies; immune-mediated inflammatory diseases; infection; inflammatory bowel disease; malignancy; psoriasis; rheumatoid arthritis; safety